The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.

Eligibility Criteria:

• Histologically documented malignancy

• Metastatic or locally unresectable malignancy

• Patient may be responding to therapy

  • Responding Stage IIIC/IV or recurrent/refractory ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols)
  • Relapsed germ cell carcinomas
  • Relapsed lymphomas (ineligible for other BMT or SCT protocols
  • SCLC in PR or CR
  • Sarcomas in or near complete remission after induction chemotherapy
  • Stage IIIB NSCLC responding to chemotherapy
  • Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary
  • Other tumors without curative or first line therapy (not eligible for phase II or III studies)

• Aged 18 to 55 Physiologic years

  -- Performance status: PS 0-1

• Prior Treatment

  • > 1 week since surgery or RT
  • > 3 weeks since prior CT

• Informed Consent

• Required initial laboratory data:

  • White Cell Count Life ≥ 3000/ul

  • Platelet Count ≥ 100,000/ul

  • Creatinine ≤ 1.5 x normal

  • Bilirubin ≤ 1.5 x normal

  • No current metastases

    • BM Asp & Bx
    • Brain CAT

  • Creatinine Clearance ≥ 60 cc/min

  • SGOT < 2.5 x normal

• No other serious medical or psychiatric illness which would prevent informed consent or general anesthesia

  • Uncontrolled or severe cardiovascular disease including recent (< 6 months) myocardial infarction, or congestive heart failure
  • Active uncontrolled bacterial, viral, or fungal infection; or an active duodenal ulcer; until these conditions are corrected or controlled
  • Pregnancy
  • Unable to stop taking antihypertensive medication 24 hours prior to administration of Ethyol